{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:58:18Z","timestamp":1771264698280,"version":"3.50.1"},"reference-count":38,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2021,5,10]]},"DOI":"10.1253\/circrep.cr-20-0101","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T22:06:48Z","timestamp":1617660408000},"page":"273-278","source":"Crossref","is-referenced-by-count":3,"title":["Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy"],"prefix":"10.1253","volume":"3","author":[{"given":"Junya","family":"Komatsu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu-ichiro","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-ichi","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Aging Science, Kochi Medial School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Aging Science, Kochi Medial School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Aging Science, Kochi Medial School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho-ichi","family":"Kubokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohisa","family":"Hamashige","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori L","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chikamori Hospital"},{"name":"Cardiomyopathy Institute, Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implication on the projections for future prevalence. <i>Circulation<\/i> 2006; 114: 119\u2013125.","DOI":"10.1161\/CIRCULATIONAHA.105.595140"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kirchhof P, Benussi K, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Eur Heart J<\/i> 2016; 37: 2893\u20132962.","DOI":"10.5603\/KP.2016.0172"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. <i>J Am Coll Cardiol<\/i> 2015; 66: 1000\u20131007.","DOI":"10.1016\/j.jacc.2015.06.1314"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2001; 104: 2517\u20132524.","DOI":"10.1161\/hc4601.097997"},{"key":"5","unstructured":"5. Doi Y, Kitaoka H. Hypertrophic cardiomyopathy in the elderly: Significance of atrial fibrillation. <i>J Cardiol<\/i> 2001; 37(Suppl 1): 133\u2013138."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BO, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 39: 301\u2013307.","DOI":"10.1016\/S0735-1097(01)01727-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy: Results from Kochi RYOMA study. <i>Circ J<\/i> 2009; 73: 1599\u20131605.","DOI":"10.1253\/circj.CJ-09-0140"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Siontis K, Geske JB, Ong K, Nishimura R, Ommen S, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: Prevalence, clinical correlations, and mortality in a large high-risk population. <i>J Am Heart Assoc<\/i> 2014; 3: e001002.","DOI":"10.1161\/JAHA.114.001002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 39: 638\u2013645.","DOI":"10.1016\/S0735-1097(01)01778-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Binder J, Attenhofer Jost CH, Klarich KW, Connolly H, Tajik AJ, Scott CG, et al. Apical hypertrophic cardiomyopathy: Prevalence and correlates of apical outpouching. <i>J Am Soc Echocardiogr<\/i> 2011; 24: 775\u2013781.","DOI":"10.1016\/j.echo.2011.03.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Guttmann OP, Rahman MS, O\u2019Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systemic review. <i>Heart<\/i> 2014; 100: 465\u2013472.","DOI":"10.1136\/heartjnl-2013-304276"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. MacIntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2016; 133: 1901\u20131905.","DOI":"10.1161\/CIRCULATIONAHA.115.015085"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Camm CF, Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy. <i>Arrhythm Electrophysiol Rev<\/i> 2017; 6: 63\u201368.","DOI":"10.15420\/aer.2017:4:2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kubo T, Hirota T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Patients\u2019 characteristics and clinical course of hypertrophic cardiomyopathy in a regional Japanese cohort: Results from Kochi RYOMA study. <i>Circ J<\/i> 2018; 82: 824\u2013830.","DOI":"10.1253\/circj.CJ-17-0845"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2005; 45: 697\u2013704.","DOI":"10.1016\/j.jacc.2004.11.043"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Haruki S, Minami Y, Hagiwara N. Stroke and embolic events in hypertrophic cardiomyopathy: Risk stratification in patients without atrial fibrillation. <i>Stroke<\/i> 2016; 47: 936\u2013942.","DOI":"10.1161\/STROKEAHA.115.012130"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. <i>J Am Coll Cardiol<\/i> 2005; 45: 1076\u20131080.","DOI":"10.1016\/j.jacc.2004.12.067"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gruver EJ, Fatkin D, Dodds GA, Kisslo J, Maron BJ, Seideman JG, et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663 His beta-cardiac myosin heavy chain mutation. <i>Am J Cardiol<\/i> 1999; 83(Suppl 1): 13\u201318.","DOI":"10.1016\/S0002-9149(99)00251-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ogimoto A, Hamada M, Nakura J, Miki T, Hiwada K. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. <i>J Hum Genet<\/i> 2002; 47: 184\u2013189.","DOI":"10.1007\/s100380200021"},{"key":"20","unstructured":"20. Tsutsui H, Kitaoka H, Isobe M, Ide T, Ueta H, Ono M, et al. JCS 2018 guideline on diagnosis and treatment of cardiomyopathies. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/02\/JCS2018_tsutsui_kitaoka.pdf (in Japanese) (accessed May 2020)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Klues HG, Schiffers A, Maron BJ. Phenotype spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. <i>J Am Coll Cardiol<\/i> 1995; 26: 1699\u20131708.","DOI":"10.1016\/0735-1097(95)00390-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. <i>Circulation<\/i> 2000; 102: 858\u2013864.","DOI":"10.1161\/01.CIR.102.8.858"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. <i>Stroke<\/i> 1984; 15: 282\u2013284.","DOI":"10.1161\/01.STR.15.2.282"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. <i>Jpn Circ J<\/i> 1997; 61: 673\u2013681.","DOI":"10.1253\/jcj.61.673"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Guttmann OP, Pavlou M, O\u2019Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). <i>Eur J Heart Fail<\/i> 2015; 17: 837\u2013845.","DOI":"10.1002\/ejhf.316"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2017; 136: 2420\u20132436.","DOI":"10.1161\/CIRCULATIONAHA.117.029267"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gersh BJ, Maron BJ, Bonow RD, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the America College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. <i>Circulation<\/i> 2011; 124: 2761\u20132796.","DOI":"10.1161\/CIR.0b013e318223e2bd"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2014; 35: 2733\u20132779.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguchia J, Garcia-Pinilla JM, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. <i>Int J Cardiol<\/i> 2017; 248: 232\u2013238.","DOI":"10.1016\/j.ijcard.2017.08.010"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: A nationwide cohort study. <i>Chest<\/i> 2019; 155: 354\u2013363.","DOI":"10.1016\/j.chest.2018.11.009"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Xao X, Abraham NS, Sangaralingham LS, Bellolio F, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. <i>J Am Heart Assoc<\/i> 2016; 5: e003725.","DOI":"10.1161\/JAHA.116.003725"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Larsen TB, Skjoth F, Nielsen PB, Kjaldgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. <i>BMJ<\/i> 2016; 353: i3189.","DOI":"10.1136\/bmj.i3189"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012): Digest version. <i>Circ J<\/i> 2016; 80: 753\u2013774.","DOI":"10.1253\/circj.CJ-66-0122"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: A systematic review. <i>JAMA<\/i> 2015; 313: 1950\u20131962.","DOI":"10.1001\/jama.2015.4369"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Okumura T, Kimura Y, Murohara T. Prediction of thromboembolism in patients with hypertrophic cardiomyopathy. <i>Circ J<\/i> 2020; 84: 700\u2013701.","DOI":"10.1253\/circj.CJ-20-0250"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sivalokanathan S, Zghaib T, Greenland GV, Vasquez N, Kudchadkar SM, Kontari E, et al. Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging. <i>JACC Clin Electrophysiol<\/i> 2019; 5: 364\u2013375.","DOI":"10.1016\/j.jacep.2018.10.016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hohneek A, Overhoff D, Doesch C, Sandberg R, Rudic B, Tueluemen E, et al. Extent of late gadolinium enhancement predicts thromboembolic events in patients with hypertrophic cardiomyopathy. <i>Circ J<\/i> 2020; 84: 754\u2013762.","DOI":"10.1253\/circj.CJ-19-0936"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Bisbal F, Baranchuk A, Braunwald E, Bayes de Luna A, Bayes-Genis A. Atrial failure as a clinical entity: JACC review topic of the week. <i>J Am Coll Cardiol<\/i> 2020; 75: 222\u2013232.","DOI":"10.1016\/j.jacc.2019.11.013"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/5\/3_CR-20-0101\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T03:33:05Z","timestamp":1621049585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/5\/3_CR-20-0101\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-20-0101","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]}}}